Danoprevir/ritonavir - Roche

Drug Profile

Danoprevir/ritonavir - Roche

Alternative Names: Ritonavir-boosted danoprevir

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Roche
  • Developer Ascletis; Roche
  • Class Antivirals; Carboxylic acids; Cyclopropanes; Isoindoles; Macrocyclic compounds; Pyrrolidines; Small molecules; Sulfonamides; Thiazoles
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hepatitis C

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C(In volunteers) in New Zealand (PO, Tablet)
  • 31 Mar 2013 Phase-II clinical trials in Hepatitis C (Combination therapy, Treatment-naive) in Thailand (PO) after March 2013
  • 31 Mar 2013 Phase-II clinical trials in Hepatitis C in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top